The upregulation of CASZ1b in T‐ALL and its role in accelerating disease development through the PI3K/AKT/mTOR pathway highlight its potential as a therapeutic target, emphasizing the need for further investigation into its interactions with NOTCH1 and impact on chemotherapy resistance. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.